NASDAQ:SCNX Scienture Q4 2025 Earnings Results & Report $3.91 +0.15 (+3.99%) Closing price 10/12/2026 04:00 PM EasternExtended Trading$3.96 +0.05 (+1.28%) As of 10/12/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Scienture missed analyst expectations on both earnings and revenue in its Q4 2025 results, released March 30, 2026. The company reported EPS of -$44.00 versus the -$7.00 consensus estimate, while revenue of ($0.17) million fell short of the $0.49 million estimate by $0.65 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 30, 2026TimeBefore Market OpensConference Call8:00 AM ET Scienture EPS ResultsActual EPS-$44.00Consensus EPS -$7.00Beat/MissMissed by -$37.00One Year Ago EPSN/AEPS Beat Rate2 of last 6 quartersScienture Revenue ResultsActual Revenue($0.17) millionExpected Revenue$0.49 millionBeat/MissMissed by -$654.70 thousandYoY Revenue GrowthN/AUpcoming EarningsScienture's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Scienture Q4 2025 Earnings FAQ Did Scienture beat earnings estimates for Q4 2025? Scienture (NASDAQ:SCNX) reported earnings of -$44.00 per share for Q4 2025, missing the consensus estimate of -$7.00. The report was announced on Monday, March 30, 2026. What was Scienture's revenue for Q4 2025? Scienture reported revenue of ($0.17) million for Q4 2025, against a consensus estimate of $0.49 million. When is Scienture's next earnings date? Scienture's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Scienture on the company's earnings history page. Scienture Earnings HeadlinesContrasting Scienture (NASDAQ:SCNX) and Silo Pharma (NASDAQ:SILO)October 7, 2026 | americanbankingnews.comSCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and HospitalsOctober 5, 2026 | marketscreener.comMThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)What is Maxim Group's Estimate for Scienture Q3 Earnings?October 5, 2026 | americanbankingnews.comExclusive: Scienture expands institutional reach for hypertension drug with new hospital adoptionsOctober 2, 2026 | msn.comSCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and HospitalsOctober 2, 2026 | globenewswire.comSee More Scienture Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scienture? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scienture and other key companies, straight to your email. Email Address About ScientureScienture (NASDAQ:SCNX) is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Its areas of interest include neurological and psychiatric conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain. The company’s portfolio includes prescription pharmaceutical products and product candidates intended to provide alternative delivery methods or other potential benefits compared with existing treatments. Scienture has identified ZolpiMist, an FDA-approved oral spray formulation of zolpidem tartrate for the short-term treatment of insomnia, as part of its commercial and development portfolio. Scienture primarily serves the U.S. pharmaceutical market and is focused on advancing, obtaining regulatory approval for, and commercializing therapies in its targeted CNS categories. The company’s operations and product strategy may evolve as it develops its pipeline and pursues commercialization opportunities.View Scienture ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
